On February 7, 2022, Biogen Inc. and Xbrane Biopharma AB  announced that they had entered into a commercialization and license agreement related to Xcimzane, a certolizumab pegol biosimilar referencing CIMZIA.  Under the agreement, Biogen will gain exclusive global regulatory, manufacturing, and commercial rights to Xcimzane, and Xbrane will be responsible for completing pre-clinical development.  Ian Henshaw, Head of Global Biosimilars at Biogen stated, “[t]his preclinical biosimilar candidate has the potential to add another option for patients living with Rheumatoid Arthritis and other indications.”  Martin Ĺmark, CEO of Xbrane Biopharma AB, further added, “[g]iven their vast development and commercialization experience, we are convinced that Biogen is the best possible partner we could have for Xcimzane.”

According to the press release, CIMZIA's primary indications are rheumatoid arthritis, axial spondylarthrosis, psoriasis, and Chron's disease and global sales were 1.8 billion Euro in 2020.  Under the terms of the agreement, Biogen will make an upfront payment of $8 million to Xbrane, with Xbrane eligible to receive up to $80 million in potential milestone payments.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Harrison Gunn
Goodwin Procter LLP
Exchange Place
Boston
MA 02109
UNITED STATES
Tel: 6175701329
Fax: 6175231231
E-mail: JScalzi@goodwinlaw.com
URL: www.goodwinprocter.com

© Mondaq Ltd, 2022 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing